According to a ranking of the best hospitals in the U.S., the best hospital for adult cancer is the University of *******************************, which had a score of *** out of 100, as of 2025. This statistic shows the top 10 hospitals for adult cancer in the United States based on the score given by U.S. News and World Report's annual hospital ranking.

As of 2025, New York-Presbyterian hospital is the largest hospital in the United States with its eight campuses based in New York City. This was followed by AdventHealth Orlando in Florida stands as the second largest hospital in the United States, boasting an impressive 2,787 beds. Evolving landscape of U.S. hospitals Despite the decline in the total number of hospitals since 1980, the healthcare sector continues to grow in other ways. U.S. hospitals now employ about 7.5 million workers and generate a gross output of around 1,263 billion U.S. dollars. The Hospital Corporation of America, based in Nashville, Tennessee, leads the pack as the largest health system in the country, operating 222 hospitals as of February 2025. This reflects a trend towards consolidation and the rise of for-profit hospital chains, which gained prominence in the 1990s. Specialization and emergency care While bed count is one measure of hospital size, institutions also distinguish themselves through specialization and emergency care capabilities. For instance, the University of California at Los Angeles Medical Center performed 22,287 organ transplants between January 1988 and March 2025, making it the leading transplant center in the nation. In terms of emergency care, Parkland Health and Hospital System in Dallas recorded the highest number of emergency department visits in 2024, with 235,893 patients seeking urgent care.

This statistic shows the size of the 100 best hospitals in the United States in 2012, sorted by the number of beds per hospital. In 2012, ** out of the top 100 U.S. hospitals had between 100 and *** patient beds.

Context

There are all sorts of reasons why you'd want to know a hospital's quality rating.

• Your mom is having her second hip replacement. Her first one went terribly and you're nervous about how she'll do. Which hospital would you suggest she have her surgery?
• You're selecting a health plan on your state's Exchange, but your top two choices partner with different hospitals. How will you decide which plan to pick?
• Your brother has Cystic Fibrosis and has to go to the ER frequently. He hates waiting. Which hospitals/states provide care in the timeliest manner?
• Your in-laws moved to Florida recently to retire, and have been trying to convince you to move there too. You're looking for any way possible to show them that your state is better. Does your state have better hospitals?

Every hospital in the United States of America that accepts publicly insured patients (Medicaid or MediCare) is required to submit quality data, quarterly, to the Centers for Medicare & Medicaid Services (CMS). There are very few hospitals that do not accept publicly insured patients, so this is quite a comprehensive list.

Content

This file contains general information about all hospitals that have been registered with Medicare, including their addresses, type of hospital, and ownership structure. It also contains information about the quality of each hospital, in the form of an overall rating (1-5, where 5 is the best possible rating & 1 is the worst), and whether the hospital scored above, same as, or below the national average for a variety of measures.

This data was updated by CMS on July 25, 2017. CMS' overall rating includes 60 of the 100 measures for which data is collected & reported on Hospital Compare website (https://www.medicare.gov/hospitalcompare/search.html). Each of the measures have different collection/reporting dates, so it is impossible to specify exactly which time period this dataset covers. For more information about the timeframes for each measure, see: https://www.medicare.gov/hospitalcompare/Data/Data-Updated.html# For more information about the data itself, APIs and a variety of formats, see: https://data.medicare.gov/Hospital-Compare

Acknowledgements

Attention: Works of the U.S. Government are in the public domain and permission is not required to reuse them. An attribution to the agency as the source is appreciated. Your materials, however, should not give the false impression of government endorsement of your commercial products or services. See 42 U.S.C. 1320b-10.

Inspiration

Which hospital types & hospital ownerships are most common?

Which hospital types & ownerships are associated with better than average ratings/mortality/readmission/etc?

What is the average hospital rating, by state?

Which hospital types & hospital ownerships are more likely to have not submitted proper data ("Not Available" & "Results are not available for this reporting period")?

Which parts of the country have the highest & lowest density of religious hospitals?

This table shows the low, high, and average percents of discharges related to a referenced DRG (diagnosis-related group) as a share of the total discharges from the top 100 common DRGs for hospitals in the United States. The source of data for this table is FY2011 hospital charges file provided by the Centers for Medicare and Medicaid Services (CMS).

Public reporting of measures of hospital performance is an important component of quality improvement efforts in many countries. However, it can be challenging to provide an overall characterization of hospital performance because there are many measures of quality. In the United States, the Centers for Medicare and Medicaid Services reports over 100 measures that describe various domains of hospital quality, such as outcomes, the patient experience and whether established processes of care are followed. Although individual quality measures provide important insight, it is challenging to understand hospital performance as characterized by multiple quality measures. Accordingly, we developed a novel approach for characterizing hospital performance that highlights the similarities and differences between hospitals and identifies common patterns of hospital performance. Specifically, we built a semi-supervised machine learning algorithm and applied it to the publicly-available quality measures for 1,614 U.S. hospitals to graphically and quantitatively characterize hospital performance. In the resulting visualization, the varying density of hospitals demonstrates that there are key clusters of hospitals that share specific performance profiles, while there are other performance profiles that are rare. Several popular hospital rating systems aggregate some of the quality measures included in our study to produce a composite score; however, hospitals that were top-ranked by such systems were scattered across our visualization, indicating that these top-ranked hospitals actually excel in many different ways. Our application of a novel graph analytics method to data describing U.S. hospitals revealed nuanced differences in performance that are obscured in existing hospital rating systems.

According to a ranking of the best hospitals in the U.S., the best hospital for adult cardiology, heart, and vascular surgery is the ******************** in New York, which had a score of *** out of 100, as of 2025. This statistic shows the top 10 hospitals for adult cardiology, heart, and vascular surgery in the United States based on the score given by U.S. News and World Report's annual hospital ranking.

As of February 2025, the Hospital Corporation of America, based in Nashville, Tennessee, was the largest health system in the United States, with a total of 222 hospitals. HCA Healthcare is also the largest U.S. health system when ranked by the number of beds and, as expected, by net patient revenue.Hospitals in the United StatesCurrently, there are approximately 6,120 hospitals in the United States. Looking over the past decades, this figure was constantly decreasing. For example, there were nearly 7,000 hospitals in 1980. There are some 5.3 million persons employed in U.S. hospitals in full-time. Contrary to the decrease in the number of hospitals, employment has been increasing steadily. According to the Bureau of Economic Analysis, U.S. hospitals generate a total gross output of around 1,075 billion U.S. dollars. The largest portion of U.S. hospitals are non-profit facilities. A smaller share includes private-owned for-profit hospitals. In most cases, these hospitals are part of hospital chains. For-profit hospitals developed especially in the 1990s, with the aim to gain profit for their shareholders. The Hospital Corporation of America, based in Nashville, Tennessee, is the U.S. for-profit hospital operator with the highest number of hospitals.

The data provided here include hospital-specific charges for the more than 3,000 U.S. hospitals that receive Medicare Inpatient Prospective Payment System (IPPS) payments for the top 100 most frequently billed discharges, paid under Medicare based on a rate per discharge using the Medicare Severity Diagnosis Related Group (MS-DRG) for Fiscal Year (FY) 2011, 2012, and 2013. These DRGs represent more than 7 million discharges or 60 percent of total Medicare IPPS discharges.

Success.ai’s Healthcare Industry Leads Data and B2B Contact Data for US Healthcare Professionals offers an extensive and verified database tailored to connect businesses with key executives and administrators in the healthcare industry across the United States. With over 170M verified profiles, including work emails and direct phone numbers, this dataset enables precise targeting of decision-makers in hospitals, clinics, and healthcare organizations.

Backed by AI-driven validation technology for unmatched accuracy and reliability, this contact data empowers your marketing, sales, and recruitment strategies. Designed for industry professionals, our continuously updated profiles provide the actionable insights you need to grow your business in the competitive healthcare sector.

Key Features of Success.ai’s US Healthcare Contact Data:

• Comprehensive Healthcare Sector Coverage Access detailed contact information for professionals across the healthcare spectrum:

Hospital Executives: CEOs, CFOs, and COOs managing top-tier facilities. Healthcare Administrators: Decision-makers driving operational excellence. Medical Professionals: Physicians, specialists, and nurse practitioners. Clinic Managers: Leaders in small and mid-sized healthcare organizations.

• AI-Validated Accuracy and Updates

  99% Verified Accuracy: Our advanced AI technology ensures data reliability for optimal engagement. Real-Time Updates: Profiles are continuously refreshed to maintain relevance and accuracy. Minimized Bounce Rates: Save time and resources by reaching verified contacts.

• Customizable Delivery Options Choose how you access the data to match your business requirements:

API Integration: Connect our data directly to your CRM or sales platform. Flat File Delivery: Receive customized datasets in formats suited to your needs.

Why Choose Success.ai for Healthcare Data?

• Best Price Guarantee We ensure competitive pricing for our verified contact data, offering the most comprehensive and cost-effective solution in the market.

• Compliance-Driven and Ethical Data Our data collection adheres to strict global standards, including HIPAA, GDPR, and CCPA compliance, ensuring secure and ethical usage.

• Strategic Benefits for Your Business Success.ai’s US healthcare professional data unlocks numerous business opportunities:

Targeted Marketing: Develop tailored campaigns aimed at healthcare executives and decision-makers. Efficient Sales Outreach: Engage with key contacts to accelerate your sales process. Recruitment Optimization: Access verified profiles to identify and recruit top talent in the healthcare industry. Market Intelligence: Use detailed firmographic and demographic insights to guide strategic decisions. Partnership Development: Build valuable relationships within the healthcare ecosystem.

• Data Highlights 170M+ Verified Profiles 50M Direct Phone Numbers 700M Global Professional Profiles 70M Verified Company Profiles

Key APIs for Advanced Functionality

• Enrichment API Enhance your existing contact data with real-time updates, ensuring accuracy and relevance for your outreach initiatives.

• Lead Generation API Drive high-quality lead generation efforts by utilizing verified contact information, including work emails and direct phone numbers, for up to 860,000 API calls per day.

• Use Cases

1. Healthcare Marketing Campaigns Target verified executives and administrators to deliver personalized and impactful marketing campaigns.

2. Sales Enablement Connect with key decision-makers in healthcare organizations, ensuring higher conversion rates and shorter sales cycles.

3. Talent Acquisition Source and engage healthcare professionals and administrators with accurate, up-to-date contact information.

4. Strategic Partnerships Foster collaborations with healthcare institutions and professionals to expand your business network.

5. Industry Analysis Leverage enriched contact data to gain insights into the US healthcare market, helping you refine your strategies.

• What Sets Success.ai Apart?

Verified Accuracy: AI-driven technology ensures 99% reliability for all contact details. Comprehensive Reach: Covering healthcare professionals from large hospital systems to smaller clinics nationwide. Flexible Access: Customizable data delivery methods tailored to your business needs. Ethical Standards: Fully compliant with healthcare and data protection regulations.

Success.ai’s B2B Contact Data for US Healthcare Professionals is the ultimate solution for connecting with industry leaders, driving impactful marketing campaigns, and optimizing your recruitment strategies. Our commitment to quality, accuracy, and affordability ensures you achieve exceptional results while adhering to ethical and legal standards.

No one beats us on price. Period.

Introduction

EHR Industry Statistics: Electronic Health Records (EHRs) are digital versions of patient paper charts, revolutionizing healthcare by providing instant, secure access to comprehensive medical information.

They include details like medical history, diagnoses, medications, and test results, consolidating data from various sources into one accessible record.

EHRs enhance patient care by supporting better coordination among healthcare providers, improving efficiency through reduced paperwork, and enabling patient engagement via access to their records.

Challenges include high implementation costs, interoperability issues between different systems, and concerns about data privacy.

Looking ahead, advancements aim to improve interoperability, enhance data analytics, and integrate with telemedicine for more efficient and personalized healthcare delivery.

Abstract

Different countries have different health outcomes that are in part due to the way respective health systems perform. Regardless of the type of health system, individuals will have health and non-health expectations in terms of how the institution responds to their needs. In many countries, however, health systems do not perform effectively and this is in part due to lack of information on health system performance, and on the different service providers.

The aim of the WHO World Health Survey is to provide empirical data to the national health information systems so that there is a better monitoring of health of the people, responsiveness of health systems and measurement of health-related parameters.

The overall aims of the survey is to examine the way populations report their health, understand how people value health states, measure the performance of health systems in relation to responsiveness and gather information on modes and extents of payment for health encounters through a nationally representative population based community survey. In addition, it addresses various areas such as health care expenditures, adult mortality, birth history, various risk factors, assessment of main chronic health conditions and the coverage of health interventions, in specific additional modules.

The objectives of the survey programme are to: 1. develop a means of providing valid, reliable and comparable information, at low cost, to supplement the information provided by routine health information systems. 2. build the evidence base necessary for policy-makers to monitor if health systems are achieving the desired goals, and to assess if additional investment in health is achieving the desired outcomes. 3. provide policy-makers with the evidence they need to adjust their policies, strategies and programmes as necessary.

Geographic coverage

The survey sampling frame must cover 100% of the country's eligible population, meaning that the entire national territory must be included. This does not mean that every province or territory need be represented in the survey sample but, rather, that all must have a chance (known probability) of being included in the survey sample.

There may be exceptional circumstances that preclude 100% national coverage. Certain areas in certain countries may be impossible to include due to reasons such as accessibility or conflict. All such exceptions must be discussed with WHO sampling experts. If any region must be excluded, it must constitute a coherent area, such as a particular province or region. For example if ¾ of region D in country X is not accessible due to war, the entire region D will be excluded from analysis.

Analysis unit

Households and individuals

Universe

The WHS will include all male and female adults (18 years of age and older) who are not out of the country during the survey period. It should be noted that this includes the population who may be institutionalized for health reasons at the time of the survey: all persons who would have fit the definition of household member at the time of their institutionalisation are included in the eligible population.

If the randomly selected individual is institutionalized short-term (e.g. a 3-day stay at a hospital) the interviewer must return to the household when the individual will have come back to interview him/her. If the randomly selected individual is institutionalized long term (e.g. has been in a nursing home the last 8 years), the interviewer must travel to that institution to interview him/her.

The target population includes any adult, male or female age 18 or over living in private households. Populations in group quarters, on military reservations, or in other non-household living arrangements will not be eligible for the study. People who are in an institution due to a health condition (such as a hospital, hospice, nursing home, home for the aged, etc.) at the time of the visit to the household are interviewed either in the institution or upon their return to their household if this is within a period of two weeks from the first visit to the household.

Kind of data

Sample survey data [ssd]

Sampling procedure

SAMPLING GUIDELINES FOR WHS

Surveys in the WHS program must employ a probability sampling design. This means that every single individual in the sampling frame has a known and non-zero chance of being selected into the survey sample. While a Single Stage Random Sample is ideal if feasible, it is recognized that most sites will carry out Multi-stage Cluster Sampling.

The WHS sampling frame should cover 100% of the eligible population in the surveyed country. This means that every eligible person in the country has a chance of being included in the survey sample. It also means that particular ethnic groups or geographical areas may not be excluded from the sampling frame.

The sample size of the WHS in each country is 5000 persons (exceptions considered on a by-country basis). An adequate number of persons must be drawn from the sampling frame to account for an estimated amount of non-response (refusal to participate, empty houses etc.). The highest estimate of potential non-response and empty households should be used to ensure that the desired sample size is reached at the end of the survey period. This is very important because if, at the end of data collection, the required sample size of 5000 has not been reached additional persons must be selected randomly into the survey sample from the sampling frame. This is both costly and technically complicated (if this situation is to occur, consult WHO sampling experts for assistance), and best avoided by proper planning before data collection begins.

All steps of sampling, including justification for stratification, cluster sizes, probabilities of selection, weights at each stage of selection, and the computer program used for randomization must be communicated to WHO

STRATIFICATION

Stratification is the process by which the population is divided into subgroups. Sampling will then be conducted separately in each subgroup. Strata or subgroups are chosen because evidence is available that they are related to the outcome (e.g. health, responsiveness, mortality, coverage etc.). The strata chosen will vary by country and reflect local conditions. Some examples of factors that can be stratified on are geography (e.g. North, Central, South), level of urbanization (e.g. urban, rural), socio-economic zones, provinces (especially if health administration is primarily under the jurisdiction of provincial authorities), or presence of health facility in area. Strata to be used must be identified by each country and the reasons for selection explicitly justified.

Stratification is strongly recommended at the first stage of sampling. Once the strata have been chosen and justified, all stages of selection will be conducted separately in each stratum. We recommend stratifying on 3-5 factors. It is optimum to have half as many strata (note the difference between stratifying variables, which may be such variables as gender, socio-economic status, province/region etc. and strata, which are the combination of variable categories, for example Male, High socio-economic status, Xingtao Province would be a stratum).

Strata should be as homogenous as possible within and as heterogeneous as possible between. This means that strata should be formulated in such a way that individuals belonging to a stratum should be as similar to each other with respect to key variables as possible and as different as possible from individuals belonging to a different stratum. This maximises the efficiency of stratification in reducing sampling variance.

MULTI-STAGE CLUSTER SELECTION

A cluster is a naturally occurring unit or grouping within the population (e.g. enumeration areas, cities, universities, provinces, hospitals etc.); it is a unit for which the administrative level has clear, nonoverlapping boundaries. Cluster sampling is useful because it avoids having to compile exhaustive lists of every single person in the population. Clusters should be as heterogeneous as possible within and as homogenous as possible between (note that this is the opposite criterion as that for strata). Clusters should be as small as possible (i.e. large administrative units such as Provinces or States are not good clusters) but not so small as to be homogenous.

In cluster sampling, a number of clusters are randomly selected from a list of clusters. Then, either all members of the chosen cluster or a random selection from among them are included in the sample. Multistage sampling is an extension of cluster sampling where a hierarchy of clusters are chosen going from larger to smaller.

In order to carry out multi-stage sampling, one needs to know only the population sizes of the sampling units. For the smallest sampling unit above the elementary unit however, a complete list of all elementary units (households) is needed; in order to be able to randomly select among all households in the TSU, a list of all those households is required. This information may be available from the most recent population census. If the last census was >3 years ago or the information furnished by it was of poor quality or unreliable, the survey staff will have the task of enumerating all households in the smallest randomly selected sampling unit. It is very important to budget for this step if it is necessary and ensure that all households are properly enumerated in order that a representative sample is obtained.

It is always best to have as many clusters in the PSU as possible. The reason for this is that the fewer the number of respondents in each PSU, the lower will be the clustering effect which

According to cognitive market research-"Global Medical Disposables market size 2023 was XX Million. Medical Disposables Industry compound annual growth rate (CAGR) was XX% from 2024 till 2031."

  In 2023, the sterilisation supplies segment held the lead with XX% of total revenue. Infection control is critical in healthcare settings.
  The plastic resin segment dominated the market in 2023. Infection control is critical in healthcare settings.
  Hospitals dominated the market in 2023 because they provide a diverse range of medical services and treatments, including various medical specialties and procedures.
  North America accounted for XX% of the worldwide market in 2023 and is expected to maintain its dominance during the forecast period. North America boasts a highly developed and modern healthcare infrastructure, including hospitals, clinics, and medical facilities.

Current scenario of the Medical disposables market

Key drivers of the Medical Disposables market

An increase in hospital-acquired infections (HAIs) around the globe is fuelling market demand. 

HAI is becoming an increasingly serious issue in healthcare facilities around the world. According to the WHO, 10 out of every 100 hospital patients in developing countries and seven in industrialised nations suffer from HAIs. Infectious agents provide an elevated risk to health practitioners and professionals, and patients who are exposed are more likely to catch hospital-acquired diseases. According to statistical research published by the Centers for Disease Control and Prevention (CDC), such HAIs cause around 1.7 million diseases and more than 99,000 deaths in American hospitals. https://www.who.int/news/item/06-05-2022-who-launches-first-ever-global-report-on-infection-prevention-and-control#:~:text=Today%2C%20out%20of%20every%20100,will%20die%20from%20their%20HAI.

HAIs were listed among the top five leading causes of mortality. Surgical infections, urinary tract infections, lung infections, and bloodstream infections are some of the most common hospital-acquired infection types. According to the American Hospital Association, post-surgical bloodstream infections have grown by 8%, while urinary tract infections have increased by 3.6% as a result of catheter placement during surgery. As a result, the usage of medical disposables may play an important role in preventing cross-contamination and reducing the danger of infection spread, driving the market to higher standards. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501203/

Rising Diabetes Rates Will Drive Up market demand

Rapid urbanization and the growing trend towards sedentary lifestyles in both developed and emerging nations are the main causes of the increased prevalence of diabetes. According to the International Diabetes Federation, 537 million adults globally were predicted to have diabetes in 2021; 51.6% of those people were estimated to reside in China, India, the United States, Brazil, and Mexico. The rapid acceptance of these systems worldwide can be attributed to the large rise in the number of patients with type-1 or insulin-dependent type 2 diabetes. Type 1 diabetes affects around 149.5 out of every 1,000 children and teenagers worldwide, accounting for 9.8% of the total population. https://idf.org/about-diabetes/diabetes-facts-figures/ Long-term diabetes may result in foot ulcers, longer hospital stays, and a positive impact on the market during the forecast period. Despite the healthcare industry's careful efforts, many people contract hospital-acquired infections while being treated there. The Centres for Disease Control and Prevention (CDC) estimate that over 3% of patients in the United States contract hospital-acquired infections each year.

Constraints for the global Medical Disposables market

The increase in waste production limits market expansion.

The sustainable healthcare business requires effective biomedical waste management. Efficiency in processing the vast amount of generated biomedical waste became a work for the entire world, as well as a fight to manage the exuberant amount of garbage, with the outbreak of the COVID-19 pandemic, when hospitals and care centres were inundated with patients. Despite the fact that the bulk of medical waste poses no harm to human...

DISCLAIMER

Dataset consists of historical data of pre-pandemic period and doesn’t represent the current reality which may have changed due to the spikes in demand. This dataset has been generated in collaboration of efforts within CoronaWhy community.

Context

Last updated: April 26th 2020 Updates: April 14th 2020 - Added missing population data April 15th 2020 - Added Brazil statewise ICU hospital beds dataset April 21th 2020 - Added Italy, Spain statewise ICU hospital beds dataset, India statewise TOTAL hospital beds dataset April 26th 2020 - Added Sweden ICU(2019) and TOTAL(2018) beds datasets

Purpose of the dataset

I am trying to produce a dataset that will provide a foundation for policymakers to understand the realistic capacity of healthcare providers being able to deal with the spikes in demand for intensive care. As a way to help, I’ve prepared a dataset of beds across countries and states. Work in progress dataset that should and will be updated as more data becomes available and public on weekly basis.

Importance

This dataset is intended to be used as a baseline for understanding the typical bed capacity and coverage globally. This information is critical for understanding the impact of a high utilization event, like COVID-19.

Current challenges

Datasets are scattered across the web and are very hard to normalize, I did my best but help would be much appreciated.

Data sources / Acknowledgments

arcgis (USA) - https://services1.arcgis.com/Hp6G80Pky0om7QvQ/arcgis/rest/services/Hospitals_1/FeatureServer/0 KHN (USA) - https://khn.org/news/as-coronavirus-spreads-widely-millions-of-older-americans-live-in-counties-with-no-icu-beds/ datahub.io (World) - https://datahub.io/world-bank/sh.med.beds.zs eurostat - https://data.europa.eu/euodp/en/data/dataset/vswUL3c6yKoyahrvIRyew OECD - https://data.oecd.org/healtheqt/hospital-beds.htm WDI (World) - https://data.worldbank.org/indicator/SH.MED.BEDS.ZS NHP(India) - http://www.cbhidghs.nic.in/showfile.php?lid=1147 data.gov.sg (Singapore) - https://data.gov.sg/dataset/health-facilities?view_id=91b4feed-dcb9-4720-8cb0-ac2f04b7efd0&resource_id=dee5ccce-4dfb-467f-bcb4-dc025b56b977 dati.salute.gov.it (Italy)- http://www.dati.salute.gov.it/dati/dettaglioDataset.jsp?menu=dati&idPag=96 portal.icuregswe.org (Sweden) - https://portal.icuregswe.org/seiva/en/Rapport publications: Intensive Care Medicine Journal (Europe) - https://link.springer.com/article/10.1007/s00134-012-2627-8 Critical Care Medicine Journal (Asia) - https://www.researchgate.net/figure/Number-of-critical-care-beds-per-100-000-population_fig1_338520008 Medicina Intensiva (Spain) - https://www.medintensiva.org/en-pdf-S2173572713000878 news: https://lanuovaferrara.gelocal.it/italia-mondo/cronaca/2020/03/19/news/dietro-la-corsa-a-nuovi-posti-in-terapia-intensiva-gli-errori-del-passato-1.38611596 kaggle: germany - https://www.kaggle.com/manuelblechschmidt/icu-beds-in-germany brazil (IBGE) - https://www.kaggle.com/thiagobodruk/brazilianstates Manual population data search from wiki

Data columns

country,state,county,lat,lng,type,measure,beds,population,year,source,source_url - country - country of origin, if present - state - more granular location, if present - lat - latitude - lng - longtitude - type - [TOTAL, ICU, ACUTE(some data could include ICU beds too), PSYCHIATRIC, OTHER(merged ‘SPECIAL’, ‘CHRONIC DISEASE’, ‘CHILDREN’, ‘LONG TERM CARE’, ‘REHABILITATION’, ‘WOMEN’, ‘MILITARY’] - measure - type of measure (per 1000 inhabitants) - beds - number of beds per 1000 - population - population of location based on multiple sources and wikipedia - year - source year for beds and population data - source - source of data - source_url - URL of the original source

Files

for each of datasource: hospital_beds_per_source.csv

US only: US arcgis + khn (state/county granularity): hospital_beds_USA.csv

Global (state(region)/county granularity): hospital_beds_global_regional.csv

Global (country granularity): hospital_beds_global_v1.csv

Contributors

Igor Kiulian - extracting/normalizing/formatting/merging data Artur Kiulian - helped with Kaggle setup Augaly S. Kiedi - helped with country population data Kristoffer Jan Zieba - found Swedish data sources

Possible Improvements

Find and megre more detailed (state/county wise) or newer datasource

Success.ai’s Healthcare Industry Leads Data empowers businesses and organizations to connect with key decision-makers and stakeholders in the global healthcare and pharmaceutical sectors. Leveraging over 170 million verified professional profiles and 30 million company profiles, this dataset includes detailed contact information, firmographic insights, and leadership data for hospitals, clinics, biotech firms, medical device manufacturers, pharmaceuticals, and other healthcare-related enterprises. Whether your goal is to pitch a new medical technology, partner with healthcare providers, or conduct market research, Success.ai ensures that your outreach and strategic planning are guided by reliable, continuously updated, and AI-validated data.

Why Choose Success.ai’s Healthcare Industry Leads Data?

1. Comprehensive Contact Information

   • Access verified work emails, phone numbers, and LinkedIn profiles of healthcare administrators, pharmaceutical executives, R&D directors, procurement officers, and medical staff.
   • AI-driven validation ensures 99% accuracy, reducing wasted efforts and fostering efficient communication.

2. Global Reach Across Healthcare Segments

   • Includes profiles from hospitals, private clinics, pharmaceutical companies, biotech startups, research institutions, and medical supply chain partners.
   • Covers North America, Europe, Asia-Pacific, South America, and the Middle East, enabling a global perspective on healthcare systems and opportunities.

3. Continuously Updated Datasets

   • Real-time updates reflect leadership changes, organizational shifts, and emerging trends in patient care, medical innovation, and regulatory compliance.

4. Ethical and Compliant

   • Adheres to GDPR, CCPA, and other global data privacy regulations, ensuring your data usage respects legal standards and patient confidentiality norms.

Data Highlights:

• 170M+ Verified Professional Profiles: Connect with healthcare and pharmaceutical professionals, decision-makers, and influencers worldwide.
• 50M Work Emails: AI-validated for direct, accurate communication and reduced bounce rates.
• 30M Company Profiles: Gain insights into organizational structures, operational scales, and specialization areas.
• 700M Global Professional Profiles: Enriched datasets to support market analysis, product development, and strategic planning.

Key Features of the Dataset:

1. Healthcare Decision-Maker Profiles

   • Identify and engage with CEOs, CIOs, CFOs, chief medical officers, hospital administrators, clinical directors, and procurement specialists.
   • Target professionals who influence equipment purchases, medical supply chain decisions, drug trial approvals, and healthcare delivery models.

2. Detailed Business Profiles

   • Access firmographic data, including company sizes, revenue ranges, key markets, and service lines for a holistic understanding of target organizations.
   • Leverage comprehensive insights to position your products, services, or solutions as tailored fits for specific operational needs.

3. Advanced Filters for Precision Targeting

   • Filter by region, specialty (oncology, cardiology, diagnostics, etc.), hospital size, pharmaceutical focus, or research areas.
   • Align campaigns with unique healthcare demands, reimbursement models, and regulatory environments.

4. AI-Driven Enrichment

   • Profiles enriched with actionable data enable personalized messaging, highlight value propositions, and enhance engagement outcomes with healthcare stakeholders.

Strategic Use Cases:

1. Sales and Business Development

   • Present medical devices, pharma products, or healthcare IT solutions to hospital administrators, chief medical officers, and procurement managers.
   • Build relationships with decision-makers who oversee budgeting, supplier selection, and patient care initiatives.

2. Market Research and Product Innovation

   • Analyze trends in patient treatments, drug pipelines, and healthcare infrastructure to inform R&D and product roadmaps.
   • Identify emerging specialties, new treatment modalities, and growth markets to focus marketing, sales, and investment efforts.

3. Strategic Partnerships and Alliances

   • Connect with R&D directors, biotech executives, or hospital groups to explore collaborations, clinical trials, and joint ventures.
   • Foster partnerships that accelerate product development, enhance patient outcomes, and drive long-term competitiveness.

4. Recruitment and Talent Acquisition

   • Target HR professionals and department heads seeking qualified medical staff, researchers, pharmaceutical reps, and administrative personnel.
   • Offer staffing, training, or professional development services to healthcare institutions aiming to improve service delivery and compliance.

Why Choose Success.ai?

1. Best Price Guarantee
   • Access high-quality, verified data at...

The Sepsis Diagnosis market was valued at USD 1.20 Billion in 2022 and will reach USD 2.5 Billion by 2030, registering a CAGR of 9.9% for the forecast period 2023-2030. Market Dynamics of Sepsis Diagnostic

Key Drivers of Sepsis Diagnostic Market

Increasing prevalence of sepsis

Sepsis is a life-threatening condition caused by a severe infection. The global prevalence of sepsis has been rising, creating a significant demand for effective diagnostics tools. The growing awareness about sepsis and its early detection has led to an increased emphasis on sepsis diagnostics. Around 30% of COVID-19 patients in Seattle, United States, displayed signs of liver damage in April 2020, and about 75% reported having a suppressed immune response, Which was reported according to Global Sepsis Alliance. They also revealed that among the non-survivors around 50% of patients had a secondary infection, almost 100% of the non-survivours had sepsis and about 70% had septic shock.

Technological advancements

The development of innovative diagnostic technologies has significantly improved the accuracy and speed of sepsis detection. Advanced molecular diagnostic techniques, biomarkers, and automated systems have enabled early and accurate diagnosis of sepsis, leading to better patient management. The newly developed test uses microelectrode to analyze the patient's blood and can provide final results in around two and a half minutes. Thus technological advancements continue to drive the growth of the sepsis diagnostics market.

Key Restraining Factors for Sepsis Diagnostic Market

Cost Constraints

Sepsis diagnostics tests, especially advanced molecular and genomic techniques, can be expensive. High costs associated with these tests may pose a challenge for their widespread adoption, particularly in resource-limited settings or regions with inadequate healthcare budgets. The cost of sepsis management in U.S. hospitals ranks highest among admissions for all disease states. For example, in 2013, sepsis accounted for more than $24 billion in hospitals, the second most costly being osteoarthritis at $17 billion and the third most costly being childbirth at $13 billion. The timing of sepsis diagnosis is critical in terms of outcomes given the acute and significant impact of the condition., Poor sepsis outcomes are observed when diagnosis and treatment are delayed resulting in the loss of money. Thus the cost is one of the main restraining factors in sepsis diagnosis.

Regulatory and Reimbursement Issues

The regulatory approval process for new sepsis diagnostic tests can be lengthy and complex. Additionally, reimbursement policies and coverage for sepsis diagnostics may vary among different healthcare systems and regions. These factors can impact the market dynamics and hinder the adoption of new diagnostic technologies.

Key Trends of for Sepsis Diagnostic Market

Shift Toward Biomarker-Based Diagnostics

There is increasing research into biomarkers like Procalcitonin (PCT), C-reactive protein (CRP), and lactate levels that offer more precise and earlier detection of sepsis.

Integration of Artificial Intelligence and Machine Learning

AI-powered diagnostic platforms are being developed to analyze patient data and predict sepsis onset more accurately and earlier than traditional methods.

Rise in Demand for Molecular Diagnostics

Technologies like PCR and next-generation sequencing (NGS) are gaining traction for their accuracy in detecting sepsis-causing pathogens quickly.

Impact of the COVID-19 Pandemic on the Sepsis Diagnostic Market: COVID-19 has negatively impacted the market. The management of sickness and medication adherence is made more difficult by lockdowns and isolation during pandemics. The industry will also be impacted by the lack of accessibility to medical facilities for standard care and pharmaceutical administration. Stress, hopelessness, and unsupportive results in social isolation, there may be a decrease in sepsis treatment adherence throughout the pandemic which has affected the overall market. According to the Global Sepsis Alliance, around 30% of COVID-19 patients have evidence of liver injury and around 75% reported a depressed immune response. Moreover, COVID-19 patients pose a higher risk of developing coinfections. The study revealed that among the non-survivors, around 50% of patients had a secondary infection, alm...

Success.ai’s Healthcare Industry Leads Data for the North American Healthcare Sector provides businesses with a comprehensive dataset designed to connect with healthcare organizations, decision-makers, and key stakeholders across the United States, Canada, and Mexico. Covering hospitals, pharmaceutical firms, biotechnology companies, and medical equipment providers, this dataset delivers verified contact information, firmographic details, and actionable business insights.

With access to over 170 million verified professional profiles and 30 million company profiles, Success.ai ensures your outreach, market research, and strategic initiatives are powered by accurate, continuously updated, and AI-validated data. Backed by our Best Price Guarantee, this solution is your key to success in the North American healthcare market.

Why Choose Success.ai’s Healthcare Industry Leads Data?

1. Verified Contact Data for Precision Targeting

   • Access verified work emails, phone numbers, and LinkedIn profiles of healthcare executives, clinical managers, procurement officers, and compliance leaders.
   • AI-driven validation ensures 99% accuracy, reducing bounce rates and improving engagement efficiency.

2. Comprehensive Coverage of North America’s Healthcare Sector

   • Includes profiles of organizations such as hospitals, private clinics, research facilities, biotech firms, and medical supply distributors.
   • Gain visibility into the unique healthcare dynamics of the United States, Canada, and Mexico, including regional trends, regulatory differences, and market opportunities.

3. Continuously Updated Datasets

   • Real-time updates reflect changes in leadership, organizational structures, service offerings, and market activities.
   • Ensure your outreach and strategy stay relevant and aligned with the rapidly evolving healthcare industry.

4. Ethical and Compliant

   • Adheres to GDPR, CCPA, and other global privacy regulations, ensuring responsible and compliant use of data for your campaigns.

Data Highlights:

• 170M+ Verified Professional Profiles: Engage with decision-makers and influencers across North America’s healthcare sector.
• 30M Company Profiles: Access detailed firmographic data, including organization sizes, revenue ranges, and geographic footprints.
• Decision-Maker Contacts: Connect with CEOs, CMOs, clinical directors, R&D leaders, and procurement managers shaping healthcare strategies.
• Operational Insights: Understand supply chains, service lines, and product pipelines within the healthcare ecosystem.

Key Features of the Dataset:

1. Healthcare Decision-Maker Profiles

   • Identify and connect with healthcare leaders driving innovation, procurement decisions, and patient care delivery.
   • Engage with professionals responsible for technology adoption, regulatory compliance, and resource management.

2. Advanced Filters for Precision Targeting

   • Filter companies by sector (hospitals, biotech, pharma, medical devices), geographic location, revenue size, or workforce composition.
   • Tailor your outreach to align with the unique needs and priorities of North American healthcare organizations.

3. Market and Operational Insights

   • Analyze trends such as telemedicine adoption, value-based care initiatives, and investments in AI and automation.
   • Leverage these insights to position your solutions effectively within a rapidly transforming industry.

4. AI-Driven Enrichment

   • Profiles enriched with actionable data allow for personalized messaging, highlight your value propositions, and improve engagement outcomes with healthcare stakeholders.

Strategic Use Cases:

1. Sales and Lead Generation

   • Offer technology solutions, medical devices, or consulting services to healthcare organizations seeking operational improvements.
   • Build relationships with procurement managers, clinical directors, and decision-makers responsible for resource allocation.

2. Marketing and Demand Generation

   • Target marketing teams and outreach coordinators within healthcare organizations to promote software solutions, diagnostic tools, or patient engagement platforms.
   • Leverage verified contact data to launch impactful email and multi-channel marketing campaigns.

3. Regulatory Compliance and Risk Mitigation

   • Connect with compliance officers and legal teams responsible for adhering to healthcare regulations and standards.
   • Present solutions for streamlined reporting, risk management, and quality assurance processes.

4. Recruitment and Workforce Optimization

   • Engage HR professionals and hiring managers in recruiting healthcare talent, from clinical staff to administrative roles.
   • Provide staffing solutions, training platforms, or workforce management tools tailored to healthcare environments.

Why Choose Success.ai?

1. Best Price Guarantee
   • Access premium-q...

The global Germanium-68 Gallium-68 Generators market is experiencing robust growth, driven by the increasing demand for PET (Positron Emission Tomography) imaging in oncology and other medical applications. The market, estimated at $150 million in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033. This growth is fueled by several key factors, including the rising prevalence of cancer globally, advancements in PET imaging technology leading to improved diagnostic accuracy and treatment planning, and the growing adoption of targeted therapies requiring precise imaging guidance. Hospitals and diagnostic centers constitute the largest application segments, reflecting the essential role of these generators in advanced medical imaging workflows. The market is segmented by generator activity levels (e.g., 50 mCi and 100 mCi), with higher activity generators gaining traction due to their enhanced imaging capabilities and reduced scan times. However, the market faces some restraints, including the relatively high cost of generators, the need for specialized handling and regulatory approvals, and the limited availability of trained personnel for operation and maintenance. Despite these challenges, the long-term outlook for the Germanium-68 Gallium-68 Generators market remains positive. Technological innovations, such as the development of more efficient and cost-effective generators, are expected to drive further market expansion. The increasing collaborations between pharmaceutical companies and generator manufacturers to develop novel radiopharmaceuticals also contribute to the market's growth potential. Furthermore, government initiatives promoting advancements in nuclear medicine and the expansion of healthcare infrastructure in emerging economies are expected to fuel market growth in the coming years. The competitive landscape features both established players and emerging companies, leading to innovation and market diversification. Regional variations in market penetration exist, with North America and Europe currently dominating the market, although significant growth opportunities are anticipated in Asia-Pacific and other developing regions as healthcare infrastructure improves.

The global market for Compound α-Ketoacid Tablets is experiencing robust growth, driven by increasing prevalence of metabolic disorders and rising demand for effective treatment options. The market, estimated at $500 million in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching approximately $900 million by 2033. This growth is fueled by several key factors, including the expanding geriatric population susceptible to metabolic diseases, increased awareness about the benefits of α-ketoacid therapy, and ongoing research leading to improved formulations and broader applications. The market segmentation reveals a preference for 100-tablet boxes, which currently holds a larger market share compared to 96-tablet boxes, reflecting economies of scale in manufacturing and distribution. Hospitals constitute the largest application segment, driven by the need for readily available and effective treatments in institutional settings. Key players like Fuyuan Pharmaceutical, Fresenius Kabi, and Beijing Hihealth Pharma are shaping the competitive landscape through strategic investments in research and development, expansion into new markets, and strategic partnerships. Geographic variations in market penetration exist, with North America and Europe currently leading in adoption due to advanced healthcare infrastructure and higher disposable incomes. However, emerging economies in Asia-Pacific are showing promising growth potential, driven by rising healthcare expenditure and increasing awareness of metabolic health. Growth is, however, constrained by the high cost of treatment, the need for specialized prescription, and potential side effects associated with prolonged use. The competitive landscape is characterized by both established pharmaceutical giants and regional players. Companies are focusing on product differentiation, improved efficacy, and convenient dosage forms to gain a competitive edge. Future growth will depend on factors such as regulatory approvals for new formulations, technological advancements in drug delivery systems, and successful outcomes from ongoing clinical trials exploring the therapeutic potential of Compound α-Ketoacid Tablets in new therapeutic areas. The market will also witness increased focus on patient education and awareness campaigns to improve understanding and adoption of α-ketoacid therapy. Further expansion into emerging markets will be crucial for long-term growth and profitability.

The global Deployable Field Hospitals market size was valued at USD XX million in 2025 and is projected to grow at a CAGR of XX% from 2025 to 2033, reaching USD XX million by 2033. The market growth is driven by the rising prevalence of natural disasters, conflicts, and humanitarian crises, which demand immediate and effective medical assistance. Additionally, advancements in medical technologies, such as modular and lightweight designs, are enhancing the capabilities and efficiency of deployable field hospitals. Key market segments include application (military use, civilian use), type (under 50 bed, 50-100 bed, 100+ bed, others), and region (North America, South America, Europe, Middle East & Africa, Asia Pacific). Military use accounts for a significant market share due to the increasing need for rapid and agile medical support in conflict zones. Civilian use is also growing, driven by the need for disaster relief and humanitarian aid in areas affected by natural disasters or other emergencies. Leading companies in the market include BLU-MED Response Systems, Losberger, HDT Global, Odulair LLC, Karmod, KF Mobile Systems, and Weatherhaven. The Asia Pacific region is expected to witness substantial growth due to the increasing frequency and severity of natural disasters, particularly in China and India.